Skip to main content
. 2023 Sep 30;15(19):4223. doi: 10.3390/nu15194223

Table 1.

Summary of the basic characteristics of included studies broken down by supplement.

Supplement
(Total Number of Studies)
Type of Studies Data Sample Size Population Dose Range Treatment Length Range
Vitamin C
(n = 5)
P: 1 (20%)
CO: 4 (80%)
Sys: 5 (100%)
Dia: 4 (80%)
Sys: 122
Dia: 114
Healthy: 4 (80%)
General: 1 (20%)
200–1000 mg/day 2–52 weeks
Vitamin D
(n = 29)
P: 29 (100%)
CO: 0 (0%)
Sys: 29 (100%)
Dia: 28 (96.6%)
Sys: 4897
Dia: 4578
Healthy: 9 (31.0%)
General: 8 (27.6%)
Obese: 8 (27.6%)
Postmenopausal: 4 (13.8%)
200–8000 IU/day 2–208 weeks
Vitamin E
(n = 7)
P: 5 (71.4%)
CO: 2 (28.6%)
Sys: 7 (100%)
Dia: 5 (71.4%)
Sys: 302
Dia: 240
Healthy: 6 (85.7%)
Postmenopausal: 1 (14.3%)
50–320 mg/day 3–26 weeks
Calcium
(n = 21)
P: 20 (95.2%)
CO: 1 (4.8%)
Sys: 21 (100%)
Dia: 21 (100%)
Sys: 4534
Dia: 4525
Healthy: 12 (57.1%)
General: 3 (14.3%)
Obese: 3 (14.3%)
Postmenopausal: 3 (14.3%)
162–2000 mg/day 4–208 weeks
Magnesium
(n = 18)
P: 14 (77.8%)
CO: 4 (22.2%)
Sys: 18 (100%)
Dia: 18 (100%)
Sys: 1575
Dia: 1575
Healthy: 11 (61.1%)
Obese: 4 (22.2%)
General: 3 (16.7%)
212–636 mg/day 4–26 weeks
Potassium
(n = 12)
P: 7 (58.3%)
CO: 5 (41.7%)
Sys: 12 (100%)
Dia: 12 (100%)
Sys: 1096
Dia: 1096
Healthy: 7 (58.3%)
General: 5 (41.7%)
24–100 mmol/day
(938.4–3910 mg/day)
3–26 weeks
Total (n = 87) P: 71 (81.6%)
CO: 16 (18.4%)
Sys: 87 (100%)
Dia: 83 (95.4%)
Sys: 12,526
Dia: 12,128
Healthy: 44 (50.6%)
General: 20 (23.0%)
Obese: 15 (17.2%)
Postmenopausal: 8 (9.2%)

The number of parallel versus cross-over studies, number of studies reporting systolic and diastolic data, and number of each type of population is given in n (%), representing the frequency of findings. The denominator for this frequency is noted in the first column. Dosage and treatment length are given as ranges. P represents parallel trials, CO represents cross-over trials, Sys represents systolic blood pressure data, and Dia represents diastolic blood pressure data.